Diethylpropion
| Diethylpropion | |
|---|---|
| Salts [] | |
|---|---|
| Diethylpropion hydrochloride | |
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 205.30 g/mol [1] |
| Melting point | 168 [1] |
| Decomposition | When heated to decomp it emits very toxic fumes of /hydrogen chloride and nitrogen oxides./ /Diethylpropion hydrochloride/ [1] |
| Solubility | White or creamy white, small crystals or crystalline powder; characteristic, mildly aromatic odor; 1 g sol in: about 0.6 mL water, about 0.6 ml chloroform, 1 ml absolute methanol, 1 ml alcohol; practically insoluble in ether /Diethylpropion hydrochloride/ [1] |
| Predicted LogP | 2.8 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C13H19NO |
| IUPAC name | 2-(diethylamino)-1-phenylpropan-1-one |
| SMILES | CCN(CC)C(C)C(=O)C1=CC=CC=C1 |
| InChI | InChI=1S/C13H19NO/c1-4-14(5-2)11(3)13(15)12-9-7-6-8-10-12/h6-11H,4-5H2,1-3H3 |
| InChIKey | XXEPPPIWZFICOJ-UHFFFAOYSA-N |
| CAS number | 90-84-6 |
| UNII | Q94YYU22B8 |
| PubChem CID | 7029 |
| Pharmacokinetics[] | |
|---|---|
| Elimination half-life | 4–6 hours (metabolites)[3] |
| Excretion | Urine (>75%) |
| Routes of administration | By mouth |
| Toxicity [] | |
|---|---|
| LD50 | Mouse: - Oral: 600 mg/kg [1] |
Diethylpropion (also known as Amfepramone, Diethylpropione, Amfepramon, Amphepramone, Nopropiophenone, Adiposon, Amphepramon, Frekentine, Danylen or Magrene) is a prodrug and stimulant substance of the amphetamine and cathinone class.
Chemistry
Salts []
Stereochemistry []
Diethylpropion is a racemic mixture of the enantiomers (optical activity ( + / - )).
| Stereoisomerism |
|---|
| Stereoisomers from PubChem |
Druglikeness
Lipinski's rule of five
Diethylpropion matches Lipinski's rule of five.Reagents
There are currently 6 reagent-interactions on DrugsPRO
| Reagent | Color change | Description |
|---|---|---|
| Marquis | no color change | |
| Mecke | light olive | |
| Mandelin | light brown | |
| Liebermann | light yellow | |
| Froehde | no color change | |
| Gallic | no color change |
Pharmacology
ATC Classification
- alimentary tract and metabolism (A)
- antiobesity preparations, excl. diet products (A08)
- antiobesity preparations, excl. diet products (A08A)
- centrally acting antiobesity products (A08AA)
- amfepramone (A08AA03)
MeSH Classification
- appetite depressants (M0001614)
Mechanism of action []
Diethylpropion is an amphetamine that stimulates neurons to release or maintain high levels of a particular group of neurotransmitters known as catecholamines; these include dopamine and norepinephrine. High levels of these catecholamines tend to suppress hunger signals and appetite. Diethylpropion (through catecholamine elevation) may also indirectly affect leptin levels in the brain. It is theorized that diethylpropion can raise levels of leptin which signal satiety. It is also theorized that increased levels of the catecholamines are partially responsible for halting another chemical messenger known as neuropeptide Y. This peptide initiates eating, decreases energy expenditure, and increases fat storage. [1]
Metabolism
Diethylpropion acts as a prodrug for:
| Metabolic pathways [] |
|---|
Diethylpropion |
Interactions []
Medical side effects []
60 side effects listed on drug labels in SIDER 4.1 (diethylpropion).
- Agranulocytosis
- Alopecia
- Anxiety
- Arrhythmia
- Constipation
- Diarrhoea
- Dizziness
- Somnolence
- Dyskinesia
- Dysmenorrhoea
- Dyspnoea
- Dysuria
- Ecchymosis
- Epilepsy
- Dermatitis
- Rash
- Gynaecomastia
- Headache
- Cardiac valve disease
- Pulmonary hypertension
- Leukopenia
- Mydriasis
- Nausea
- Nervousness
- Feeling jittery
- Tension
- Palpitations
- Polyuria
- Urine output increased
- Cerebrovascular accident
- Tachycardia
- Tremor
- Erythema
- Urticaria
- Vomiting
- Dry mouth
- Agitation
- Pancytopenia
- Pulmonary arterial hypertension
- Malaise
- Discomfort
- Feeling abnormal
- Ill-defined disorder
- Myalgia
- Musculoskeletal discomfort
- Chest pain
- Dyspepsia
- Gastrointestinal disorder
- Abdominal discomfort
- Dysphoria
- Convulsion
- Euphoric mood
- Erectile dysfunction
- Psychotic disorder
- Vision blurred
- Blood pressure increased
- Emotional distress
- Hyperhidrosis
- Electrocardiogram change
- Insomnia
Indications
- Anorexia
- Diabetes mellitus
- Hyperlipidaemia
- Hypertension
- Obesity
- Weight decreased
Subjective effects []
Experience reports
Legal status []
- Australia: Diethylpropion is a Schedule 4.
- Brazil: Diethylpropion is a B2.[4]
- Canada: Diethylpropion is a Schedule G (CDSA IV).[5][6]
- Germany: Diethylpropion is Prescription only (Anlage III for higher doses).
- United Kingdom: Diethylpropion is a Class C under the "Misuse of Drugs Act 1971".
- United States: Diethylpropion is a Schedule IV under the "Controlled Substances Act".
- European Union: Diethylpropion is Prescription only.[7][8]
External links []
- Diethylpropion (Wikipedia)
- Diethylpropion (PubChem)
- Diethylpropion (Wikidata)
- Diethylpropion (DrugBank)
- Diethylpropion (ChEMBL)
- Diethylpropion (ChEBI)
- Diethylpropion (Common Chemistry)
- Diethylpropion (HMDB)
- Diethylpropion (KEGG)
- Diethylpropion (EPA DSSTox)
- Diethylpropion (Effect Index)
- Diethylpropion (UNII)
- Diethylpropion (SIDER)
- Diethylpropion (Erowid)
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 7029, Diethylpropion. Accessed November 22, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/7029
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Diethylpropion. UNII: Q94YYU22B8. Global Substance Registration System. Accessed November 22, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/Q94YYU22B8
SPC-DOC_PL 16133-0001. Medicines Healthcare products Regulatory Agency. 18 November 2011. http://www.mhra.gov.uk/home/groups/spcpil/documents/spcpil/con1396847771265.pdf
RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 2023-03-31. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992
Tenuate Product information. Health Canada. 25 April 2012. https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=16693
Nobesine Product information. Health Canada. 25 April 2012. https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=9263
Amfepramone. List of nationally authorized medicinal products. https://www.ema.europa.eu/en/documents/psusa/amfepramone-list-nationally-authorised-medicinal-products-psusa/00000138/202006_en.pdf
Amfepramone-containing medicinal products. European Medicines Agency (EMA). 12 February 2021. https://www.ema.europa.eu/en/medicines/human/referrals/amfepramone-containing-medicinal-products
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 11:58:22 |
| drugspro | ok | 2026-11-20 11:58:18 |
| erowid | ok | 2026-11-20 11:58:27 |
| gsrs | ok | 2026-11-20 11:58:19 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0015072) | 2026-11-20 11:58:18 |
| kegg | ok | 2026-11-20 11:58:20 |
| pubchem | ok | 2026-11-20 11:58:17 |
| missing (no r/tripreports posts mention it) | 2026-11-20 11:58:18 | |
| sider | ok | 2026-11-20 11:58:18 |
| structure | ok | 2026-11-20 11:58:18 |
| wikipedia | ok | 2026-11-20 11:58:18 |